A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subjects with Advanced Solid Tumors

Cancer Categories

Breast,Gynecologic

Karmanos Trial ID

2024-053

NCT ID

NCT06431594

Age Group

Adult

Scope

National

Phase

Phase I

Principal Investigator

Ira
Winer, M.D., Ph.D., FACOG
Oncology - Gynecologic, Oncology - Surgical View Profile

Objective:

Primary Objective:

To evaluate the safety and tolerability of GSK5733584 administered intravenously in subjects with advanced solid tumors to establish MTD or maximum applicable dose (MAD).

Secondary objectives:

To evaluate the PK profile of GSK5733584 administered intravenously in subjects with advanced solid tumors.
To evaluate the clinical activity of GSK5733584 administered intravenously in subjects with advanced solid tumors.
To evaluate the immunogenicity of GSK5733584 administered intravenously in subjects with advanced solid tumors.
To further evaluate the safety and tolerability of GSK5733584 administered intravenously in subjects with advanced solid tumors

Request an Appointment

Refer a Patient

NCI Dictionary of Cancer Terms

KCI Clinical Trials App

Eligibility

Inclusion Criteria:

Males or females aged 18 years or older (≥18 years).
Participants with pathologically confirmed advanced solid tumor (who have failed or are intolerant to standard of care).
PROC cohort

Histologically documented, advanced (metastatic and/or unresectable) high-grade serous/endometrioid ovarian, primary peritoneal, or fallopian tube cancer.
Must have received or are intolerant to 1 but no more than 3 lines of prior systemic therapy.
Platinum-resistant disease, defined as progression or relapse within 6 months after the completion of platinum-based therapy.
Must have had prior bevacizumab if the participant was considered a candidate for this regimen and the regimen is locally available.
Participants with known Folate receptor-α (FR-α) expressing tumors must have received mirvetuximab soravtasine if the participants was considered a candidate for this regimen and the regimen is locally available.
Participants with known Breast cancer susceptibility gene (BRCA) mutated tumors should have received a Poly adenosine diphosphate-ribose polymerase (PARP) inhibitor if the participant was considered a candidate for this regimen and the regimen is locally available.
Maintenance therapy will be considered part of the preceding line of therapy (ie, not counted independently).

Endometrial cancer cohort

Histologically documented, advanced (metastatic and/or unresectable) or recurrent endometrial cancer.
Must have received or are intolerant to 1 but no more than 2 lines of prior systemic therapy.
Must have had prior platinum and PD(L)-1 inhibitor (in same regimen or in separate regimens), if considered a candidate for this regimen and the regimen is locally available.
Maintenance therapy will be considered part of the preceding line of therapy (ie, not counted independently
All epithelial histologies are permitted including carcinosarcoma.

Participants have at least one target lesion as assessed per the RECIST 1.1
Tumor tissue from a newly obtained biopsy or archival tumor tissue is required for retrospective detection of B7 homolog 4 (B7-H4) expression by Immunohistochemistry (IHC) in central laboratory and other biomarker analysis. Tissue from a newly obtained biopsy is preferred. If a newly obtained biopsy is not feasible, archival tumor tissue within 2 years prior to the first dose of study drug is acceptable.
Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 to 2 and no deterioration within 2 weeks before the first dose.
Have a life expectancy of at least 12 weeks.

Exclusion Criteria:

Have received any of B7-H4-targeted therapies.
Have received any of cytotoxic chemotherapy drugs, anti-tumor traditional Chinese medicines or other anti-tumor drugs within 28 days prior to the first dose of study drug; or need to continue these drugs during the study.
Have received locoregional radiation therapy within 2 weeks prior to the first dose of study drug; more than 30% of bone marrow irradiation or wide-field radiation therapy within 4 weeks prior to the first dose of study treatment.
Presence of pleural/abdominal effusion/ascites requiring clinical intervention; presence of pericardial effusion
Major surgery within 4 weeks prior to the first dose of study treatment.
Evidence of brain metastasis unless asymptomatic.
Has inadequate bone marrow reserve or hepatic/renal functions.
Mean Fridericia-corrected QT interval (QTcF) > 470 millisecond (msec) on resting ECG.
Evidence of current clinically significant arrhythmias or ECG abnormalities
Risk factors of prolonged QTc or arrhythmia events,
Left ventricular ejection fraction (LVEF) < 50%.
Have severe, uncontrolled or active cardiovascular disorders, serious or poorly controlled hypertension, clinically significant bleeding symptoms or serious arteriovenous thromboembolic events
Any evidence of current Interstitial lung disease (ILD) or pneumonitis or a prior history of ILD or pneumonitis requiring high-dose systemic glucocorticoids.
Have received prior therapy with topoisomerase inhibitors or topoisomerase inhibitor Antibody-drug conjugate (ADCs)
PROC

Primary platinum refractory not permitted.
Non-epithelial carcinoma, clear-cell, mucinous, germ-cell, low-grade serous, or low-grade endometrioid carcinoma not permitted.

Locations

Karmanos Cancer Institute - Detroit Headquarters

4100 John R
Detroit, MI 48201
Get Directions

Phone: 1-800-527-6266

Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

31995 Northwestern Hwy
Farmington Hills, MI 48334
Get Directions

Phone: 1-800-527-6266

Applicable Disease Site

Therapies, Drugs, Devices